Cargando…
Neuromuscular blockade management in patients with COVID-19
This narrative review evaluates the evidence for using neuromuscular blocking agents (NMBA) in patients being treated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While large prospective randomized-controlled trials (RCTs) are lacking at this point in time, smaller observational...
Autores principales: | Chaves-Cardona, Harold, Hernandez-Torres, Vivian, Kiley, Sean, Renew, Johnathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Anesthesiologists
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342831/ https://www.ncbi.nlm.nih.gov/pubmed/33934595 http://dx.doi.org/10.4097/kja.21106 |
Ejemplares similares
-
Reply to the Commentary on “An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant”
por: Paredes, Stephania, et al.
Publicado: (2023) -
An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant
por: Paredes, Stephania, et al.
Publicado: (2023) -
Neuromuscular blockade management in the critically Ill patient
por: Renew, J. Ross, et al.
Publicado: (2020) -
Comparison of onset of neuromuscular blockade with electromyographic and acceleromyographic monitoring: a prospective clinical trial
por: Chaves-Cardona, Harold E., et al.
Publicado: (2023) -
Neuromuscular Blockade in the Pre- and COVID-19 ARDS Patients
por: Tsolaki, Vasiliki, et al.
Publicado: (2022)